Atezolizumab for Urothelial Carcinoma

On March 8, 2021, Genentech voluntarily withdrew the US indication for atezolizumab (Tecentriq) for the treatment of prior-platinum treated metastatic urothelial carcinoma.

In 2016, the FDA granted accelerated approval to atezolizumab, a PD-L1 blocking antibody, for prior-platinum treated metastatic urothelial carcinoma based on tumor response rate and duration of response data from the phase 2 IMvigor210 study (ClinicalTrials.gov: NCT02108652).

Results from a subsequent confirmatory phase 3 trial (IMvigor211; ClinicalTrials.gov: NCT02302807) showed that treatment with atezolizumab did not meet the primary endpoint of overall survival in the PD-L1 high patient population. Continued approval of this indication was contingent upon the results of IMvigor211, the original post marketing requirement (PMR) to confirm clinical benefit.


Continue Reading

While the IMvigor130 study (ClinicalTrials.gov: NCT02807636), which was subsequently designated as the PMR, will still continue until the final analysis, the Company voluntarily withdrew the indication based on the principles of the FDA’s Accelerated Approval Program.

Six Indications Still to Be Reviewed

On March 11, the FDA announced that 6 additional indications with results from confirmatory trials that have not verified clinical benefit will be evaluated by the FDA’s Oncologic Drugs Advisory Committee.7 The meeting, which will take place on April 27-29, will review the following products, all approved through the Accelerated Approval Program:

  • Atezolizumab (Tecentriq) in combination with paclitaxel protein-bound for unresectable locally advanced or metastatic triple-negative breast cancer in patients whose tumors express PD-L1.
  • Atezolizumab (Tecentriq) for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.
  • Pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.
  • Pembrolizumab (Keytruda) for patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1, with disease progression on or after 2 or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.
  • Pembrolizumab (Keytruda) for patients with hepatocellular carcinoma who have been previously treated with sorafenib.
  • Nivolumab (Opdivo) as a single agent for patients with hepatocellular carcinoma who have been previously treated with sorafenib.

In a statement, Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research, said: “This public meeting of the advisory committee creates an opportunity for external oncology experts and patients with cancer to share input and perspective with the FDA. After this advisory meeting, our staff will consider the committee’s comments and will make final decisions regarding continuing approval of each indication.”

Additional information about the meeting can be found here.

References

  1. Food and Drug Administration Accelerated Approval Program. U.S. Food and Drug Administration. https://www.fda.gov/drugs/information-health-care-professionals-drugs/accelerated-approval-program. Accessed March 10, 2021.
  2. Ribeiro TB, Buss L, Wayant C, Nobre MRC. Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018. [published online July 24, 2020].  PLoS ONEdoi.org/10.1371/journal.pone.0236345.
  3. Bristol Myers Squibb statement on Opdivo (nivolumab) small cell lung cancer U.S. indication. [press release]. Bristol Myers Squibb; December 29, 2020.
  4. Voluntary withdrawal of Imfinzi indication in advanced bladder cancer in the US. [press release]. AstraZeneca; February 22, 2021.
  5. Merck provides update on Keytruda® (pembrolizumab) indication in metastatic small cell lung cancer in the US. [press release]. Kenilworth, NJ: Merck; March 1, 2021.
  6. Genentech provides update on Tecentriq U.S. indication in prior-platinum treated metastatic bladder cancer. [press release]. South San Francisco, CA: Genentech; March 8, 2021.
  7. FDA In Brief: FDA Oncologic Drugs Advisory Committee to Review Status of Six Indications Granted Accelerated Approval. U.S. Food and Drug Administration. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-oncologic-drugs-advisory-committee-review-status-six-indications-granted-accelerated. Accessed March 11, 2021.

This article originally appeared on MPR